NEW YORK (GenomeWeb) – Paradigm today announced a partnership to provide its PCDx next-generation sequencing-based cancer diagnostic test to Translational Drug Development's (TD2) affiliated oncology provider networks.

The deal will provide oncologists in TD2's networks access to Paradigm's test in order to make tailored treatment decisions for patients.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.